June 2026 in “HAL (Le Centre pour la Communication Scientifique Directe)” This article presents the SH-1 molecule as a novel AR antagonist for androgenetic alopecia treatment, highlighting its tissue-specific action and potential for commercialization, but provides no new clinical results.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This source describes SH‑1 as a next-generation androgen receptor antagonist designed for localized treatment of androgenetic alopecia, aiming to reverse follicular miniaturization while maintaining endocrine balance. Unlike traditional therapies, SH‑1 offers tissue-specific action, avoiding systemic effects.
June 2026 in “HAL (Le Centre pour la Communication Scientifique Directe)” This infographic compares the safety profiles of SH‑1, a cosmetic ingredient, which showed no systemic absorption, and PP405, an investigational drug with dose-dependent systemic uptake and potential threshold breaches, highlighting differences in safety between cosmetic and investigational substances according to this report.
July 2026 in “Marine Drugs” In this mouse study, researchers found that orally administered low-molecular-weight fish collagen peptides significantly improved hair regrowth by both enhancing growth-promoting pathways and reducing inhibitory mechanisms.
2 citations
,
February 2024 in “International Journal of Molecular Sciences” This study reported that in a mouse model, Negative Pressure Wound Therapy promotes wound healing by modulating inflammatory responses and increasing dickkopf-related protein 1, which encourages the differentiation of Hair Follicle Stem Cells into epidermal cells.